Effect of combination of Taurine, N-Acetyl Cysteine and Coenzyme Q10 (Uralbu TM) on uACR in Diabetic Patients

Safety and Efficacy of a fixed dose combination of Taurine, N-Acetyl Cysteine and Coenzyme Q10 (Uralbu TM) on Microalbuminuria in Type II Diabetic Patients: A Randomized Controlled, Double-Blind Trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/084293

Enrollment

Registered

2025-04-07

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications

Interventions

Intervention1: Uralbu (Taurine + N-Acetyl Cysteine + Coenzyme Q10) : Taurine 500mg, N-Acetyl Cysteine 150mg and Coenzyme Q10 60mg as a fixed dose combination, twice daily, after food for 6 months Co

Eligibility

Inclusion criteria

Inclusion criteria: Type 2 Diabetes mellitus patients above 18 years of age and microalbuminuria with Urine albumin creatinine ratio ranging between 30-300 mg/g in three consecutive samples collected over two weeks before the beginning of the study. Patients willing to give informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients who were taking short-acting insulins, rosiglitazone, pioglitazone, GLP-1 receptor analogues, sodium glucose co-transporter 2 inhibitors or anti-obesity drugs within three months before the beginning of the study. 2. Patients with a history of myocardial infarction, stroke, or transient ischemic attack within 06 months of the beginning of the study. 3. Patients who had non-diabetic renal failure or urinary tract infection, or those who had received a kidney transplant were not included in the study. 4. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Fixed dose combination of Taurine 500 mg, N-Acetyl Cysteine 150mg and Coenzyme Q10 60 mg (Uralbu) may provide improvement on microalbuminuria patients by decreasing Urine Albumin-Creatinine Ratio (ACR). Timepoint: Fixed dose combination of Taurine 500 mg, N-Acetyl Cysteine 150mg and Coenzyme Q10 60 mg (Uralbu) may provide improvement on microalbuminuria patients by decreasing Urine Albumin-Creatinine Ratio (ACR) after 12th and 24th week of treatment	—

Measure

Time frame

Fixed dose combination of Taurine 500 mg, N-Acetyl Cysteine 150mg and Coenzyme Q10 60 mg (Uralbu) may provide improvement on microalbuminuria patients by decreasing Urine Albumin-Creatinine Ratio (ACR). Timepoint: Fixed dose combination of Taurine 500 mg, N-Acetyl Cysteine 150mg and Coenzyme Q10 60 mg (Uralbu) may provide improvement on microalbuminuria patients by decreasing Urine Albumin-Creatinine Ratio (ACR) after 12th and 24th week of treatment

—

Secondary

Measure	Time frame
Fixed dose combination of Taurine 500 mg, N-Acetyl Cysteine 150mg & Coenzyme Q10 60 mg (Uralbu) may provide improvement on microalbuminuria patients by decreasing CKD-EPI Creatinine Cystatin-C level & eGFR Value. Timepoint: Fixed dose combination of Taurine 500 mg, N-Acetyl Cysteine 150mg & Coenzyme Q10 60 mg (Uralbu) may provide improvement on microalbuminuria patients by decreasing CKD-EPI Creatinine Cystatin-C level & eGFR Value after 12th & 24th week of treatment.	—

Measure

Time frame

Fixed dose combination of Taurine 500 mg, N-Acetyl Cysteine 150mg & Coenzyme Q10 60 mg (Uralbu) may provide improvement on microalbuminuria patients by decreasing CKD-EPI Creatinine Cystatin-C level & eGFR Value. Timepoint: Fixed dose combination of Taurine 500 mg, N-Acetyl Cysteine 150mg & Coenzyme Q10 60 mg (Uralbu) may provide improvement on microalbuminuria patients by decreasing CKD-EPI Creatinine Cystatin-C level & eGFR Value after 12th & 24th week of treatment.

—

Countries

India

Contacts

Public ContactE Arun

SRM Institute of Science and Technology

jagapharmd2013@gmail.com9449277556

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026